No. | Author (year) | Study design | Animal characteristics | Intervention characteristics | Outcomes | |||
---|---|---|---|---|---|---|---|---|
Disease model | Disease induction | Animal model Gender | Age | Source; (Origin) | Dose; delivery; timing; frequency | Lung architecture/function | ||
1 | Ahmadi (2016) | Asthma | Ovalbumin | Wistar rats Male | Adult | Bone marrow | 50 μl; IV; 1-day post sensitization; × 1 | Tracheal reactivity |
2 | Ahmadi (2017) | Asthma | Ovalbumin | Wistar rats Male | Adult | Bone marrow | 50 μl; IT; 1-day post sensitization; × 1 | Histologic lung injury |
3 | Aslam (2009) | BPD | Hyperoxia | FVB mice Mixed | Neonate | Bone marrow | 50 μl; IV; postnatal day 4; × 1 | Alveolarization RVH Vasculogenesis |
4 | Chailakhyan (2014) | ALI | LPS from E. coli | Wistar rats Male | NR | Bone marrow | 1000 μl; IV; 1 h after LPS injection; × 1 | Histologic lung injury |
5 | Chaubey (2018) | BPD | Hyperoxia | C57BL/6 mice NR | Neonate | Human umbilical cord tissue | 100 μl; IP; PN2 and PN4; × 1 | Alveolarization RVH Pulmonary artery pressure |
6 | Cruz (2015) | Asthma | Aspergillus fumigatus sensitization | C57/BL6 mice Male | Adult | Bone marrow | 200 μl; IV; 14 days after Aspergillus challenge; × 1 | Histologic lung injury |
7 | Curley (2013) | ALI/ ARDS | High stretch mechanical ventilation | Sprague–Dawley rats (pathogen-free) Male | Adult | Bone marrow | 300 μl; IT; 2.5–3 h post injury initiation; × 1 | Alveolarization Histologic lung injury Compliance Wet, dry lung weight ratios Blood gas |
8 | Felix (2020) | PF | Bleomycin | Wistar rats NR | Adult | Adipose tissue | 200 μl; IV; 10 days after induction; × 1 | Histologic lung injury Fibrosis |
9 | Gülaşı (2015) | BPD | Hyperoxia | Wistar rats Mixed | Neonate | Bone marrow | 25 μl; IT; on the 11th day; at every inspiration; × 1 | Alveolarization |
10 | Hansmann (2012) | BPD | Hyperoxia | FVB mice Mixed | Adult | Bone marrow | 50 μl; IV postnatal day 14; × 1 | Alveolarization Fibrosis Compliance/Resistance |
11 | Hayes (2015) | VILI/ALI | Ventilator-induced | Sprague–Dawley rats Male | Adult | Bone marrow | 500 μl; 1.5 h after injury; × 1 | Alveolarization Permeability Compliance |
12 | Huh (2011) | Emphysema (COPD) | Cigarette smoke-induced | Lewis rats Female | Adult | Bone marrow | 300 μl; IV; 6 months of age; × 10 | Alveolarization Vascularization Pulmonary artery pressure |
13 | Hwang (2016) | LIRI | Left lung was clamped, re-ventilated, and perfused | Sprague–Dawley rats Male | Adult | Bone marrow | 200 μl, IT, 30 min prior to disease induction; × 1 | Permeability |
14 | Ionescu (2012) | ARDS | LPS from E. coli | C57/BL6 mice Male | Adult | Bone marrow | 30 μl; IT; 4 h post-LPS exposure; × 1 | Permeability Histologic lung injury |
15 | Kennelly (2016) | COPD | Receptor knockout | NOD-SCID IL-2rgnull Mice NR | NR | Human bone marrow | IN, day 0 + 6 h; × 2 | Alveolarization |
16 | Keyhanmanesh (2018) | Asthma | Ovalbumin | Wistar rats Male | Adult | Bone marrow | 50 μl; IV, single dose, day 33; repeated dose days 33–35 | Histologic lung injury |
17 | Li (2018) | PF | Silica | Wistar rats Female | Adult | Bone marrow | 1 mL, IT, days 1 and 4 post-silica; × 2 | Fibrosis Histologic lung injury |
18 | Lu (2015) | ARDS | LPS from E. coli | C57/BL6 mice Male | NR | Adipose tissue | 200 μl; IV; 4 h post-LPS exposure; × 1 | Permeability |
19 | Pierro (2012) | BPD | Hyperoxia | Newborn rats Mixed | Neonate | Human umbilical cord blood | 7 μl/g; IP; postnatal day 4–21 (prevention studies) or from postnatal day 14–28 (regeneration studies); × 18 vs. × 15 | Alveolarization Vascularization RVH Compliance Exercise capacity |
20 | Rahbarghazi (2019) | Asthma | Ovalbumin | Wistar rats Male | Adult | Bone marrow | 50 μl; IT; day 33; × 1 | Histologic lung injury |
21 | Rathinasabapathy (2016) | PH | Monocrotaline | Sprague–Dawley rats Male | Adult | Adipose tissue | 100 μl; IV; 14 days post-MCT exposure; × 1 | Vasculogenesis RVH Fibrosis |
22 | Sadeghi (2019) | SM | CEES | C57/BL6 mice Male | 6–8 weeks | Adipose tissue | 500 μl; IP; start week 28; × 8 | Fibrosis |
23 | Shen (2014) | PF | Bleomycin | Wistar rats Female | NR | Bone marrow | 200 μl; IT; at 6 h and on day 3 following disease induction; × 2 | Fibrosis |
24 | Su (2019) | ALI | LPS from E. coli | C57BL/6 mice Male | 8–12 weeks old | NR | 200 μl; IV; 4 h after disease induction; × 1 | Lung injury |
25 | Sutsko (2012) | BPD | Hyperoxia | Sprague–Dawley rats Mixed | Neonate | Bone marrow | 50 μl; IT; postnatal day 9; × 1 | Alveolarization Vascularization RVH |
26 | Tropea (2012) | BPD | Hyperoxia | FVB mice NR | Neonate | Bone marrow | 50 μl; IV; postnatal day 4; × 1 | Alveolarization |
27 | Wakayama (2015) | ARDS | Bleomycin | C57/BL6J mice Female | Adult | Human exfoliated deciduous teeth | 500 μl; IV; 24 h post-bleomycin exposure; × 1 | Fibrosis |
28 | Waszak (2012) | BPD | Hyperoxia | Sprague–Dawley rats Mixed | Neonate | Bone marrow | 1 μl/g; IP; postnatal day 0 to postnatal day 21; × 22 | Alveolarization Vasculogenesis RVH Pulmonary artery pressure |
29 | Zhao (2014) | Bronchiolitis obliterans | Transplanted donor trachea | C57BL/6 mice Male | Adult | Placenta derived | Volume NR; IT; 3rd day after transplantation; × 1 | Tracheal luminal obliteration |